<DOC>
	<DOCNO>NCT01850303</DOCNO>
	<brief_summary>For elderly patient , treatment Non Small Cell Lung Cancer base monotherapy IFCT-0501 trial begin 2006 , demonstrate bitherapy ( carboplatin paclitaxel ) good monotherapy term overall survival progression free survival . The current recommendation administer carboplatin base bitherapy ( 4 6 cycle ) . After treatment stop progression initiation second line treatment . The risk strategy confront rapid disease progression free interval . Indeed , 1/3 patient whose disease control chemotherapy receive 2nd line . The concept maintenance base continuous therapeutic pressure order preserve therapeutic profit obtain treatment 1st line ( induction chemotherapy ) . There two type maintenance : - continuous maintenance therapy consist continue treatment initially associate platinum disease progression . - switch maintenance consist introduce new treatment end induction chemotherapy The two type validate several trial . The marketing authorization pemetrexed enlarged maintenance non squamous carcinoma . Gemcitabine good tolerance profile make possible use maintenance strategy . Several trial evaluate maintenance product show benefit term progression free survival . The objective trial evaluate switch maintenance elderly patient control disease 4 cycle chemotherapy carboplatin-paclitaxel .</brief_summary>
	<brief_title>MODEL ( Maintenance Versus Observation After inDuction Chemotherapy Non-progressing Elderly Patients With Advanced Non-small Cell Lung Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically document Non Small Cell Lung Cancer non resectable non irradiable stage III stage IV EGFR wild type non feasible EGFR 90 &gt; Age â‰¥ 70 ECOG Performance status : 0 , 1 2 MiniMental Test Status ( MMS ) &gt; 23 Mixed nonsmall cell small cell tumor Patients EGFR mutate tumor Patient EML4ALK translocation Evolutive symptomatic metastasis central nervous system Superior vena cava syndrome Calcemia &gt; 2,70 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Elderly</keyword>
	<keyword>lung cancer</keyword>
	<keyword>switch</keyword>
	<keyword>maintenance</keyword>
	<keyword>Elderly patient ( 70 89 year )</keyword>
	<keyword>NSCLC</keyword>
</DOC>